Pharma Wakes Up To Transformative Progress In Hearing Loss Research
Executive Summary
The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector.
You may also be interested in...
Protecting Against Hearing Loss: Acousia Pursues A New Approach
German biotech Acousia Therapeutics closes a series B round with corporate and institutional VC firms, and aims to advance its drugs into clinical trials for hearing loss associated with cancer chemotherapy.
Auris Medical's Second Phase III Tinnitus Trial Disappoints
Auris Medical Holding's investigational tinnitus product, Keyzilen, has failed to meet its primary efficacy endpoint in an interim analysis of a second Phase III trial, adding to a series of clinical disappointments over the past few years for the Swiss biotech.
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.